Drug Trial Radar · NCT03475342
World Maternal Antifibrinolytic Trial_2
Last checked: Nov 19, 2026Latest source record: Jan 10, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
15,068
Actual
Start
Aug 24, 2019
Primary completion
Sep 20, 2023
Study completion Oct 29, 2023
Sponsor
- Lead sponsor
- London School of Hygiene and Tropical MedicineAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Wellcome Trust; Bill and Melinda Gates Foundation
- First posted
- Mar 23, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- Female only
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Postpartum haemorrhage (PPH) is responsible for about 100,000 maternal deaths every year, almost all of which occur in low and middle income countries. When given within three hours of birth, tranexamic acid reduces deaths due to bleeding in women with PPH by almost one third. However, for many women, treatment of PPH is too late to prevent death and severe morbidities. Over one-third of pregnant women in the world are anaemic and many are severely anaemic. We now want to do the WOMAN-2 trial to see if giving tranexamic acid can prevent PPH and other severe outcomes in women with moderate and severe anaemia.
Conditions
- Intrapartum - Moderate and Severe Anaemia
Interventions
Tranexamic AcidDrug
Ampoules and packaging for both arms will be identical in appearance.
PlaceboOther
Ampoules and packaging for both arms will be identical in appearance.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Postpartum Haemorrhage (cause will be described)Time frame: 24 hours after administration of the trial medication or at discharge from hospital, whichever is earlier
Locations
41 sites in 4 countries. Site status is shown where the registry gives one.
Mother & Child Hospital
Akure, Nigeria
University of Medical Sciences Teaching Hospital
Akure, Nigeria
Adeoyo Maternity Hospital
Ibadan, Nigeria
Ilorin General Hospital
Ilorin, Nigeria
Muhammad Abdullahi Wase Specialist Hospital
Kano, Nigeria
Ladoke Akintola University of Technology Teaching Hospital
Ogbomoso, Nigeria
State Hospital
Oyo, Nigeria
Ayub Teaching Hospital (Unit A)
Abbottabad, Pakistan
Ayub Teaching Hospital (Unit C)
Abbottabad, Pakistan
Ayub Teaching Hospital Unit B
Abbottabad, Pakistan
Bahawalpur Victoria Hospital
Bahawalpur, Pakistan
Aziz Bhatti Teaching Hospital
Gujrat, Pakistan
MCH PIMS
Islamabad, Pakistan
Military Hospital
Islamabad, Pakistan
Civil Hospital
Karachi, Pakistan
Jinnah Postgraduate Medical Centre
Karachi, Pakistan
Koohi Goth Hospital
Karachi, Pakistan
Jinnah Hospital
Lahore, Pakistan
Services Hospital
Lahore, Pakistan
Sir Ganga Ram Hospital Unit 1
Lahore, Pakistan
Sir Ganga Ram Hospital Unit 2
Lahore, Pakistan
Sir Ganga Ram Hospital Unit 3
Lahore, Pakistan
Sir Ganga Ram Hospital Unit 4
Lahore, Pakistan
Chandka SMBBMU Sheikh Zaid Woman Hospital Unit 1
Larkana, Pakistan
Chandka SMBBMU Sheikh Zaid Woman Hospital Units 2 & 3
Lārkāna, Pakistan
Nishtar Hospital Unit 1
Multan, Pakistan
Nishtar Hospital Unit 2
Multan Khurd, Pakistan
Nishtar Hospital Unit 3
Multan Khurd, Pakistan
Bolan Medical Centre
Quetta, Pakistan
Benazir Bhutto Shaheed Hospital
Rawalpindi, Pakistan
Federal Government Polyclinic
Rawalpindi, Pakistan
Holy Family Hospital
Rawalpindi, Pakistan
Mount Meru Regional Referral Hospital
Arusha, Tanzania
Amana Regional Referral Hospital,
Dar es Salaam, Tanzania
Muhimbili National Hospital
Dar es Salaam, Tanzania
Temeke Regional Referral Hospital
Dar es Salaam, Tanzania
Dodoma Regional Referral Hospital
Dodoma, Tanzania
Tumbi Regional Referral Hospital, Kibaha
Kibaha, Tanzania
Mwananyamala Regional Referral Hospital
Kinondoni, Tanzania
Mbeya Zonal Referral Hospital
Mbeya, Tanzania
Showing 40 of 41 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.